← All Spyre Therapeutics, INC filings

Spyre Therapeutics, INC Form 4 insider transactions

NASDAQ
SYRE
Spyre Therapeutics, INC
Form 4: Spyre Therapeutics Director Acquires Stock Options
Director Jeffrey W. Albers acquired stock options for 11,323 shares of Spyre Therapeutics, Inc. common stock on May 14, 2024.
NASDAQ
SYRE
Spyre Therapeutics, INC
Form 4: Spyre Therapeutics Director Stelzer Acquires Stock Options
Director Laurie Stelzer acquired stock options for 11,323 shares of Spyre Therapeutics common stock on May 14, 2024.
NASDAQ
SYRE
Spyre Therapeutics, INC
Form 4: Spyre Therapeutics Director Acquires Stock Options
Director Michael Thomas Henderson acquired stock options for 11,323 shares of Spyre Therapeutics, Inc. on May 14, 2024.
NASDAQ
SYRE
Spyre Therapeutics, INC
Form 4: Spyre Therapeutics Director Exchange Preferred Stock for Common Stock
Fairmount Funds Management LLC, along with related entities and individuals, converted Series A Preferred Stock into Common Stock of Spyre Therapeutics, Inc. on April 25, 2024.